ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1044

Ocular Manifestations in Inflammatory Bowel Disease. Study of 1442 Patients from a Single Referral Center

Lara Sanchez-Bilbao1, David Martinez-Lopez2, Inigo Gonzalez-Mazon3, Maria José García-García4, Montserrat Rivero-Tirado4, Beatriz Castro4, Javier Crespo4, Miguel Ángel González-Gay5 and Ricardo Blanco1, 1Hospital Universitario Marques de Valdecilla, Santander, Spain, 2Hospital Universitario Marques de Valdecilla, Santander (SPAIN), Spain, 3Hospital Universitario Marques de Valdecilla, Bezana, Spain, 4Hospital Universitario Marqués de Valdecilla, Santander, Cantabria, Spain, 5Hospital Universitario Marques de Valdecilla, Santander, Cantabria, Spain

Meeting: ACR Convergence 2020

Keywords: Comorbidity, Eye Disorders, Inflammation

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 8, 2020

Title: Miscellaneous Rheumatic & Inflammatory Diseases Poster II: Sarcoidosis, Interstitial Lung Disease, & Inflammatory Eye Disease

Session Type: Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Inflammatory bowel disease (IBD), which includes Crohn’s disease (CD), and Ulcerative colitis (UC) are related to Spondyloarthritis (SpA). Ocular manifestations (OM) are well-stablished in SpA but not in IBD. It has been classically reported that whereas uveitis with SpA is predominantly anterior, unilateral, sudden, and limited; in IBD it is bilateral, posterior, insidious, and chronic (Lyons & Rosenbaum JT. Arch Ophthalmol 1997; 115:61-4).

In a large unselected series of IBD, we study the OM and assess; a) epidemiological, clinical features, b) the relationship with extraintestinal manifestations

Methods: Study of all consecutive patients from a single University Hospital during the last 40 years with: a) IBD (CD and UC), and b) OM: uveitis and scleral pathology diagnosed by clinical features and slit-lamp.

Results: OM were present in 42 (2.9%) (25 women/17 men) (84 eyes) of 1442 IBD patients; OM included the uveitis group (UG) (n=23; 1.6%) and the scleral pathology group (SG) (n=19, 1.32%) (TABLE).
The most common pattern in SG was episcleritis (n=16; 84.21%) and scleritis (n=3). In UG, uveitis was typically anterior (n=18; 78.3%), unilateral (n=19; 82.6%), sudden (n=19; 82.6%), and limited (n=12; 52.2%).
The comparative study between SG vs UG showed in UG a significant predominance of women and UC. Also, a non-significative higher frequency in Pyoderma gangrenosum, erythema nodosum and joint involvement was observed in UG.
After a mean follow-up of 15.2±9.97 years, extraintestinal manifestations were observed in 100% of patients, being articular forms (n=16; 38.10%) the most common type. In addition, joint/axial flare is more related to the presence of uveitis (p=0.038).

Conclusion: Both uveitis and episcleritis are equally frequent OM in IBD. Although uveitis is more infrequent in IBD than in SpA, it is also anterior, unilateral, sudden and limited in contrast with published data from selected series.


Disclosure: L. Sanchez-Bilbao, None; D. Martinez-Lopez, Lilly, 2; I. Gonzalez-Mazon, None; M. García-García, None; M. Rivero-Tirado, None; B. Castro, None; J. Crespo, None; M. González-Gay, None; R. Blanco, None.

To cite this abstract in AMA style:

Sanchez-Bilbao L, Martinez-Lopez D, Gonzalez-Mazon I, García-García M, Rivero-Tirado M, Castro B, Crespo J, González-Gay M, Blanco R. Ocular Manifestations in Inflammatory Bowel Disease. Study of 1442 Patients from a Single Referral Center [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/ocular-manifestations-in-inflammatory-bowel-disease-study-of-1442-patients-from-a-single-referral-center/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/ocular-manifestations-in-inflammatory-bowel-disease-study-of-1442-patients-from-a-single-referral-center/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology